Table 5.
Comparing the serum anti-AP3D1 antibody levels of HDs versus those of patients with esophageal squamous cell carcinoma (ESCC) and colorectal carcinoma (CRC).
| Patient group | Type of value | s-AP3D1-Ab |
|---|---|---|
| HD | Average | 15,169 |
| SD | 7065 | |
| Cutoff values | 29,299 | |
| Total No | 64 | |
| Positive No | 2 | |
| Positive (%) | 3.10% | |
| ESCC | Average | 29,537 |
| SD | 13,468 | |
| Total No | 64 | |
| Positive No | 27 | |
| Positive (%) | 42.20% | |
| P value (vs. HD) | < 0.001 | |
| CRC | Average | 20,639 |
| SD | 8,659 | |
| Total No | 64 | |
| Positive No | 10 | |
| Positive (%) | 15.60% | |
| P value (vs. HD) | < 0.001 |
The s-AP3D1-Ab levels examined using AlphaLISA in HDs and patients with ESCC and CRC are shown. Purified AP3D1-GST proteins were used as antigens. The numbers shown are as described in Table 1. P-values of < 0.05 and positive rates of > 10% are marked in bold font. The plots for these data are shown in Fig. 5a.